All questionsIndication: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection3 questions · 2 sourcesIndicationWhat is Biktarvy approved for?“BIKTARVY® is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing ≥14 kg with no antiretroviral (ARV) treatment history; or with an ARV treatment history and not virologically suppressed, with no known or suspected substitutions associated with resistance to the integrase strand inhibitor class, emtricitabine, or tenofovir; or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL) on a stable ARV regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir.” (opens the source at this quote in a new tab)CopyFlagCan Biktarvy be used in people with prior HIV treatment who are not virologically suppressed?“Use of BIKTARVY in those with an antiretroviral treatment history and not virologically suppressed is supported by a scientific rationale that this population is expected to have similar virologic response rates to those with no history of antiretroviral treatment provided that the virus is susceptible to the individual components of the regimen. Because limited clinical trial data are available supporting the efficacy of BIKTARVY in patients with baseline INSTI resistance substitutions, this indication states use in individuals with an antiretroviral treatment history and who are not virologically suppressed with no evidence of known or suspected substitutions associated with” (opens the source at this quote in a new tab)CopyFlag“resistance to the INSTI class, rather than only to bictegravir. Additionally, this indication states the individuals should have no known or suspected substitutions associated with resistance to emtricitabine, or tenofovir [see Clinical Studies (14.2 and 14.5)].” (opens the source at this quote in a new tab)CopyFlagDrug namesWhat is the generic name for Biktarvy?“BIKTARVY® (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use” (opens the source at this quote in a new tab)CopyFlag